BriaCell Therapeutics Corp.

Update 2017 September 19

OTCQB: BCTXFTSX-V: BCT

Forward-Looking Statements

2

Except for historical information, this presentation contains forward-looking statements, whichreflect BriaCell’s current expectations regarding future events. These forward-looking statementsinvolve known and unknown risks and uncertainties that could cause BriaCell’s actual results todiffer materially from those statements. Those risks and uncertainties include, but are notlimited to, our ability to access capital, the successful and timely completion of clinical trials, thereceipt of all regulatory approvals and other risks detailed from time to time in our ongoingquarterly and annual filings. The forward-looking statements in this presentation are also basedon a number of assumptions which may prove to be incorrect.

Forward-looking statements contained in this presentation represent views only as of the date ofthis presentation and are presented for the purpose of assisting potential investors inunderstanding BriaCell’s business, and may not be appropriate for other purposes. BriaCell doesnot undertake to update forward-looking statements, whether written or oral, that may be madefrom time to time by or on its behalf, except as required under applicable securities legislation.

Investors are cautioned not to rely on these forward-looking statements and are encouraged toread BriaCell’s continuous disclosure documents, including its financial statements which areavailable on SEDAR at www.sedar.com.

▪ Monotherapy Study: ➢ Ongoing and is recruiting well➢ FDA requested initiation of dosing of the first 3 patients be spaced out to ensure safety.

No issues have been seen➢ 2 sites open, 2 sites to be opened➢ No safety events of note related to the vaccine➢ Abstract submitted to the San Antonio Breast Cancer meeting in December➢ Data for the first 10 subjects is anticipated in 1Q18

▪ Plans for patients who fail monotherapy to be treated in combination with immunecheckpoint inhibitors

➢ Patients with PD-L1 or PD-L2 {the target of pembrolizumab (Keytruda)} positive tumorswill be treated with BriaVax™ in combination with Keytruda

➢ Patients with PD-L1 and PD-L2 negative tumors will be treated with BriaVax™ incombination with ipilimumab (Yervoy)

➢ IND submitted, FDA review ongoing➢ Data is expected in3Q18

Clinical Trial Update

3

▪ Patients who Progress on BriaVax™ “monotherapy” are eligible to enroll

▪ Treatment cycles are every 3 weeks

▪ Each cycle consists of:

➢ Pre-dose low dose cyclophosphamide 2-3 days before BriaVax™

➢ BriaVax™

➢ Interferon-α2b ~2 & ~4 days after BriaVax™

➢ Keytruda or Yervoy ~2 or 4 days after BriaVax™

Baseline: Imaging, labs, clinical evaluation

Restage: Imaging, labs, clinical evaluation#

Restage: Imaging, labs, clinical evaluation

Restage: Imaging, labs, clinical evaluation

Restage: Imaging, labs, clinical evaluation

Non-progressive

response

OFF STUDY

Progression

Clinical Benefit May Remain on Study

Design Of The Rollover (Combination) Study

4

Progression

Non-progressive

response

† Cycles 14,15,16,17(wks 39,42,45,48)

† Cycles10,11,12,13(wks 27,30,33,36)

Cycles 6,7,8,9(wks 15,18,21,24)

Cycles* 1,2,3,4, 5(wk 0,3,6,9, 12)

▪ UC Davis GMP Facility➢ Developed a master cell bank and a working cell bank. Generated sufficient

amounts of BriaVax™ for the first 10 patients (safety and initial efficacy)➢ Both cell banks passed FDA review for quality and safety➢ Qualified potency of the vaccine up to 24 hours for overnight shipping to

distant sites

▪ KBI Biopharma, Inc.➢ Reproduced production of BriaVax™ and confirmed GM-CSF production➢ Work underway to develop an additional Master Cell Bank and a frozen

formulation of BriaVax™➢ The frozen formulation will facilitate treatment at more distant sites for our

pivotal studies and greatly simplify the supply chain

Clinical Supplies Update

5

Research Update

▪ Sanne Graeve joined the team as Senior Research Associate

▪ Work Performed at BriaCell➢ Completed simulated cell irradiation experiments to evaluate the feasibility of a frozen

formulation➢ Evaluated serum free media, an essential part of commercialization. Initial

encouraging results➢ Preliminary experiments showed the ability to detect antibodies to BriaVax™➢ Cloned BriaVax™ to develop a high GM-CSF expressing clone

▪ Research Collaboration➢ Dr. Maurizio Provenzano, MD, PhD, the University of Zurich, Switzerland: To augment

the immune response to breast cancer using BriaVax™ in conjunction with a novelimmune stimulator

➢ Patent filing anticipated in 4Q17

▪ Development of 2nd Generation BriaVax™➢ Co-express GM-CSF and interferon-α2b and additional HLA alleles- Ongoing➢ Will simplify the treatment process and allow the treatment of more patients

6

Small Molecule Program – Sapientia AcquisitionProtein Kinase C delta (PKCδ) Inhibitors

For Cancer and Fibrotic Diseases

7

▪ Novel PKCδ inhibitors active in multiple RAS transformed tumors➢ RAS transformation occurs in ~30% of cancers➢ RAS transformed cells are dependent on PKCδ, which prevents RAS degradation➢ PKCδ inhibitors induce programmed cell death in RAS transformed cancers➢ Data available on Pancreatic cancer, Melanoma, Neuroendocrine tumors (carcinoid

syndrome), and Breast cancer➢ Estimated peak-year sales of $250M to >$1B per indication➢ PKCδ inhibitors block immunosuppressive TGFβ signaling

➢ Potential synergy with BriaVax™➢ Development plans in place for specific niche tumor types readily accessed by this MOA

▪ Novel PKCδ inhibitors show promising activity in models of fibrotic disease

➢ Conservative estimation of peak year sales ~$1B per indication➢ Total value of a successful PKCδ Inhibitor in excess of $2B/year➢ Attractive safety profile based on in vivo studies and knock out mouse studies

Novel Protein Kinase Cδ Inhibitors

8

BriaVax™ Clinical Development

➢ Clinical Supplies are available for the first 10 patients (safety and initial efficacy). ➢ Data is expected in 1Q18.

➢ Abstract Submitted to the San Antonio Breast Cancer Meeting ➢ Planning to add 2 additional clinical sites to speed up the patient recruitment

Research (In Development)

➢ Frozen formulation of BriaVax ™: To simplify the storage, and shipment of the vaccineto remote locations

➢ Immunoassays: To measure antibodies and cellular responses to BriaVax™➢ Cloned BriaVax™: To develop a high GM-CSF expressing clone➢ Improved BriaVax™ response - combination with a novel type of immune simulator:

Collaboration with University of Zurich: To augment the immune response to breastcancer using BriaVax™. Patent filing anticipated in 4Q17

➢ 2nd Generation BriaVax™: To simplify the treatment process and allow the treatment ofmore patients

➢ Novel PKCδ Inhibitors: Activity against RAS transformed cancers

Summary

9

TSX: BCT.VOTCQB: BCTXF

info@BriaCell.com | 1-888-485-6340 | BriaCell.com

For Questions, please unmute your phone and introduce yourself. Alternatively, please contact us via the following info:

Email question to info@BriaCell.com

10

TSX: BCT.VOTCQB: BCTXF

info@BriaCell.com | 1-888-485-6340 | BriaCell.com

Appendix

11

Study 1: BriaVax™ Phase I/IIa ongoing

Study 2: Rollover Study BriaVax™ + Checkpoint Inhibitor

BLA

Registration Study 1

EOP2 Meeting

BriaVax™ manufacturing and validation

12

BriaVax™ Clinical Development Plan

Phase I/IIa Status:➢ GMP manufacturing sites: UC Davis GMP Facility, and KBI Biopharma➢ Clinical CRO: Cancer Insight, LLC➢ Two clinical sites open (Annadel Medical Group at Saint Joseph’s Medical Center, Santa

Rosa, CA; Florida Cancer Care, Plantation, FL), 2 additional sites opening➢ Interim Data is expected in 1Q2018 on the first 10 patients in Study 1

EOP2: End of Phase II meeting with FDABLA: Biologics Licensing Agreement

1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q

2017 2018 2019 2020 2021 2022

-5

0

5

10

15

20

25

GM

-CSF

[n

g/1

mill

ion

cel

ls &

day

]GM-CSF secretion by irradiated BriaVax™ and BriaTest™ cells

BriaVax™ continued to secrete GM-CSF >24 hours after irradiation. BriaVax™ can be shipped overnight.

BriaVax™ Stability For Shipping

13

Frozen Formulation Development

METHOD

➢ Cells treated with CKD602, which blocks celldivision without immediate cell death; achemical way to simulate irradiation

➢ Cells frozen (“cryo”) using two differentFDA-approved viable-cell freezing media(CS5,CS10)

➢ Cell viability evaluated prior to freezing (pre-cryo) and after thawing (post-cryo)

➢ CONCLUSION: good viability after freezingand thawing supports the use of the frozenformulation

Frozen Vaccine

✓ Easy storage

✓ Readily shipped

✓ Consistency for vaccine preparation for different sites

14

H03 - 1:5 Patient R-1

Baseline Post-Treatment

E04 - 1:5 Patient R-2

Data from Patient A003 in the Original Study indicates that antibodies to BriaVax™ can be monitored. This may predict response to the vaccine treatment. More dots in the bluecircles and shift of the curve to the right indicate more antibodies binding to BriaVax™ cells.

Detection of Antibodies to BriaVax™

15

Statistics

Events % of Vis Mean GeoMean Median CV

All events 1400 100 104 63 58 161

H-2 363 26 265 215 186 101

Statistics

Events % of Vis Mean GeoMean Median CV

All events 2762 100 406 187 168 172

H-2 1779 64 595 366 316 136

BriaVax™ Clone D6

METHOD

✓ Defined number of BriaVax™ cells orClone D6 of BriaVax™, counted & seeded.

✓ Cells left in culture for 3 days

✓ Supernatants harvested & evaluated forGM-CSF production by ELISA

✓ GM-CSF production calculated asnanograms per one million cells per day

✓ CONCLUSION: Clone D6 produces moreGM-CSF than parent BriaVax™

Clone D6 of BriaVax™:

✓ Grows faster – Easier Production

✓ Produces more GM-CSF

✓ Potentially improved potency

✓ May provide additional IP

0

5

10

15

20

25

30

35

Regular Culture Clone D6GM

-CSF

in n

g /

1 m

illio

n c

ells

/ 1

day

GM-CSF ProductionRelative to Cell Numbers at Harvest

16

➢ RAS transformation occurs in ~30% of cancers➢ RAS transformed cells are dependent on PKCδ,

which prevents RAS degradation➢ PKCδ inhibitors induce programmed cell death

in RAS transformed cancers➢ Novel PKCδ inhibitors active in multiple RAS

transformed tumors➢ Attractive safety profile based on in vivo

studies and knock out mouse studies➢ PKCδ inhibitors block immunosuppressive

TGFβ signaling➢ Potential synergy with BriaVax™➢ Specific niche tumor types identified which are

readily accessed by this MOA

▪ Novel PKCδ inhibitors show promising activityin models of fibrotic disease

Novel Protein Kinase Cδ Inhibitors

17

Anti-Cancer Activity

Anti-Fibrotic Activity

Red staining means more collagen (fibrosis).This is prevented by PKCδ inhibitor B106. Negative Controls

Positive Control

Treatment

Oncology:

▪ PKCδ Inhibitors are active against RAS transformed cancers➢ Activity demonstrated against:

➢ Pancreatic cancer➢ Melanoma➢ Neuroendocrine tumors (carcinoid syndrome)➢ Breast cancer

▪ Estimated peak-year sales of $250M to >$1B per indication

Fibrotic disease:

▪ Conservative estimation of peak year sales ~$1B per indication➢ Total value of a successful PKCδ Inhibitor in excess of $2B/year➢ Expertise in medicinal chemistry, oncology and drug development enhances

probability of success➢ Potential for early partnering with IND filing, achieving proof-of-concept

Market Potential for PKCδ Inhibitors

18

Protein Kinase Cδ Development Program

SAR & Lead Development

Lead Optimization & Candidate Selection

Pre-Clinical Toxicology & ADME

IND

Phase 1/2 Study

Phase 2 Registration StudyIndication 1

NDA

Phase 2 Registration StudiesAdditional Indications

IND

Phase 1

Phase 2 POCEOP2

Phase 3

Oncology

Fibrotic Disease

SAR & Lead Development

Lead Optimization & Candidate Selection

Pre-Clinical Toxicology & ADME

3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q

2017 2018 2019 2020 2021 2022 2023

3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q

20242017 2018 2019 2020 2021 2022 2023

19NDA: New Drug Application